Ke Liu1,2,3,#, Xia Xue1,2,3,#, Haiming Qin4,5,#, Jiaying Zhu6,#, Meng Jin1,6, Die Dai6, Youcai Tang1, Ihtisham Bukhari1, Hangfan Liu1, Chunjing Qiu1, Feifei Ren1, Pengyuan Zheng1,2,3, Yang Mi1,2,3,*, Weihua Chen6,7,*
Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.072661
- 19 January 2026
Abstract Background: The gut microbiome has emerged as a critical modulator of cancer immunotherapy response. However, the mechanisms by which gut-associated metabolites influence checkpoint blockade efficacy in prostate cancer (PC) remain not fully explored. The study aimed to explore how gut metabolites regulate death-ligand 1 (PD-L1) blockade via exosomes and boost immune checkpoint inhibitors (ICIs) in PC. Methods: We recruited 70 PC patients to set up into five subgroups. The integrated multi-omics analysis was performed. In parallel, we validated the function of gut microbiome-associated metabolites on PD-L1 production and immunotherapy treatment efficacy in PC cell lines… More >